Gemcitabine diphosphate (dFdCDP) inhibits ribonucleotide reductase, which catalyses formation of deoxynucleotide triphosphates required for DNA synthesis. When incorporated into DNA, ...

Gemcitabine is then phosphorylated into gemcitabine monophosphate (dFdCMP) by deoxycytidine kinase (DCK), and dFdCMP is subsequently phosphorylated to gemcitabine diphosphate (dFdCDP) and ...

Subsequently, dFdCMP is phosphorylated to gemcitabine diphosphate (dFdCDP) by CMPK1, and then dFdCDP is converted to gemcitabine triphosphate (dFdCTP; major active metabolite) by nucleotide kinases.

Gemcitabine chemotherapy is used for advanced cancers of the breast, lungs, ovaries, and pancreas. Learn about delivery, side effects, effectiveness, and more.

Background: VEGF blockade coupled with cytotoxic chemotherapy can promote an immune-permissive tumor microenvironment that can augment response to PD-L1 inhibition. IMbrave151 (NCT04677504) is a ...

Background: Motesanib diphosphate is an oral investigational, highly selective inhibitor of VEGF, PDGF and Kit receptors. In advanced cancer, inhibition of EGFR and VEGFR, with or without chemotherapy ...

After a median follow-up of 8.2 months and 327 deaths, the median overall survival was 11.7 months among the 204 patients in the cisplatin–gemcitabine group and 8.1 months among the 206 patients ...

Yes. The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to gemcitabine — the combination was planned based ...

Gemcitabine has been used since 1997 as a treatment for advanced unresectable pancreatic cancer, and it is a potent radiosensitizer. Dr. Loehrer and colleagues examined the role, among patients ...

Data presented at the 13th European Conference (ECCO) revealed that using the combination of gemcitabine and capecitabine increased overall survival in some patients. Skip to main content.

Doctors hoped that taking Z-360 in combination with gemcitabine would work better than gemcitabine alone. But Z-360 is a new drug and doctors didn’t know how well it would work. The aims of this trial ...

The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02).